03.19.15
PharmaCell B.V. has entered an agreement with ImmunoCellular Therapeutics Ltd. to support its Phase III trial in Europe for ICT-107, a dendritic cell-based vaccine developed for glioblastoma multiforme, one of the most common and deadliest forms of brain cancer.
PharmaCell will perform a technology transfer from its U.S.-based contract manufacturing partner to its newly acquired Geleen facility in The Netherlands, and support the subsequent clinical trial for ICT-107.
Andrew Gengos, chief executive officer of ImmunoCellular Therapeutics said, “We are pleased to engage with PharmaCell who have a proven ability to support companies in establishing a robust manufacturing capability in Europe in line with the strict standards of the regulatory authorities for Phase III and early stage commercial manufacturing for ATMPs (Advanced Therapy Medicinal Products).”
Alexander Vos, chief executive officer of PharmaCell BV, said, “We are excited that ImmunoCellular Therapeutics, a global leader in cancer immunotherapy, have decided to work with us. Their decision confirms that our new Geleen facility is indeed viewed by industry experts as meeting the requirements and client expectations for late clinical stage and commercial manufacturing for ATMPs. We look forward to support ImmunoCellular in their effort to develop ICT-107 for the benefit of European patients.”
PharmaCell will perform a technology transfer from its U.S.-based contract manufacturing partner to its newly acquired Geleen facility in The Netherlands, and support the subsequent clinical trial for ICT-107.
Andrew Gengos, chief executive officer of ImmunoCellular Therapeutics said, “We are pleased to engage with PharmaCell who have a proven ability to support companies in establishing a robust manufacturing capability in Europe in line with the strict standards of the regulatory authorities for Phase III and early stage commercial manufacturing for ATMPs (Advanced Therapy Medicinal Products).”
Alexander Vos, chief executive officer of PharmaCell BV, said, “We are excited that ImmunoCellular Therapeutics, a global leader in cancer immunotherapy, have decided to work with us. Their decision confirms that our new Geleen facility is indeed viewed by industry experts as meeting the requirements and client expectations for late clinical stage and commercial manufacturing for ATMPs. We look forward to support ImmunoCellular in their effort to develop ICT-107 for the benefit of European patients.”